A Zegrea1, J Kirss2,3, T Pinta4, T Rautio5, P Varpe2, M Kairaluoma6, M Aho7, C Böckelman8, M Lavonius2. 1. Seinäjoki Central Hospital, Hanneksenrinne 7, 60220, Seinäjoki, Finland. adrian.zegrea@epshp.fi. 2. Turku University Hospital, Turku, Finland. 3. Vaasa Central Hospital, Vaasa, Finland. 4. Seinäjoki Central Hospital, Hanneksenrinne 7, 60220, Seinäjoki, Finland. 5. Oulu University Hospital, Oulu, Finland. 6. Jyväskylä Central Hospital, Jyväskylä, Finland. 7. Tampere University Hospital, Tampere, Finland. 8. Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Abstract
BACKGROUND: The aim of this study was to report the outcomes of sacral neuromodulation (SNM) in chronic pelvic pain (CPP) patients in the Finnish national cohort. METHODS: This was a register-based retrospective study, involving all the centers that provide SNM treatment in Finland. The data of all patients treated with SNM for CPP were gathered from Oulu-, Turku-, Tampere- and Helsinki University Hospitals, as well as Jyväskylä and Seinäjoki Central Hospitals. All patients who had been tested for SNM implantation prior to April 2017 were included in the study. RESULTS: A total of 51 patients were selected for SNM treatment due to CPP from 2004 until 2017. The mean follow-up time was 13.8 months (SD 22.9 months). A total of 28 patients (57%) advanced from testing to permanent stimulator implantation. There were 21 patients (41%) who had a working modulator implanted at the end of follow-up. Patients with endometriosis-related pain had a significantly higher permanent implantation rate than the overall implantation rate (88% vs. 57%; p = 0.01). The endometriosis patients also had a higher overall success rate by the end of the follow-up (75% vs. 41%; p = 0.026) CONCLUSIONS: SNM may be a viable treatment option for patients with CPP due to endometriosis. Further research on SNM treatment for endometriosis patients with refractory CPP is needed.
BACKGROUND: The aim of this study was to report the outcomes of sacral neuromodulation (SNM) in chronic pelvic pain (CPP) patients in the Finnish national cohort. METHODS: This was a register-based retrospective study, involving all the centers that provide SNM treatment in Finland. The data of all patients treated with SNM for CPP were gathered from Oulu-, Turku-, Tampere- and Helsinki University Hospitals, as well as Jyväskylä and Seinäjoki Central Hospitals. All patients who had been tested for SNM implantation prior to April 2017 were included in the study. RESULTS: A total of 51 patients were selected for SNM treatment due to CPP from 2004 until 2017. The mean follow-up time was 13.8 months (SD 22.9 months). A total of 28 patients (57%) advanced from testing to permanent stimulator implantation. There were 21 patients (41%) who had a working modulator implanted at the end of follow-up. Patients with endometriosis-related pain had a significantly higher permanent implantation rate than the overall implantation rate (88% vs. 57%; p = 0.01). The endometriosispatients also had a higher overall success rate by the end of the follow-up (75% vs. 41%; p = 0.026) CONCLUSIONS: SNM may be a viable treatment option for patients with CPP due to endometriosis. Further research on SNM treatment for endometriosispatients with refractory CPP is needed.
Entities:
Keywords:
Chronic pelvic pain; Endometriosis; Finnish national study; Sacral neuromodulation
Authors: Amr Mahran; Gina Baaklini; Daisy Hassani; Hassan A Abolella; Ahmed S Safwat; Mandy Neudecker; Adonis K Hijaz; Sangeeta T Mahajan; Steven W Siegel; Sherif A El-Nashar Journal: Int Urogynecol J Date: 2019-03-14 Impact factor: 2.894
Authors: D Mege; G Meurette; C Brochard; H Damon; E Lambrescak; J-L Faucheron; V Wyart; P-A Lehur; I Sielezneff; L Siproudhis; F Mion; I Etienney; E Houivet; V Bridoux; A-M Leroi Journal: Colorectal Dis Date: 2019-05-18 Impact factor: 3.788